News for Healthier Living

AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer

(mid dot) LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself (mid dot) Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

April 27, 2025


May 29 2025

May 28 2025

May 27 2025

May 26 2025

May 25 2025

May 24 2025

May 23 2025

May 22 2025

May 21 2025

May 20 2025

May 19 2025

May 18 2025

May 17 2025

May 16 2025